Icon

Time Sensitive

Ordering Recommendation

Use to detect and document fetal exposure to THC during approximately the last trimester of a full-term pregnancy. For panel testing that includes THC metabolite, refer to Drug Detection Panel and THC Metabolite, Umbilical Cord Tissue, Qualitative (3006371).

This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Umbilical Cord (At least 8 inches, approximately the width of a sheet of paper.)

Specimen Preparation

Drain and discard any blood. Rinse the exterior of the cord segment with normal saline or water. Pat the cord dry and transport at least 8 inches of umbilical cord in a routine urine collection cup or Security Kit for Meconium/Umbilical Drug Detection (ARUP supply #51548) available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787. (Min: 6 inches)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Cords soaking in blood or other fluid. Formalin fixed. Tissue that is obviously decomposed.

Remarks
Stability

Ambient: 1 week; Refrigerated: 3 weeks; Frozen: 1 year

Methodology

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-3 days

Reference Interval

Drugs/Drug Classes Cutoff Concentrations (ng/g)
THC-COOH 0.2

Interpretive Data

Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry

This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite.  Alternative testing is available to detect other drug exposures.  The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Absolute Minimum: 6 inches.

Hotline History

N/A

CPT Codes

80349 (Alt code: G0480)

Components

Component Test Code* Component Chart Name LOINC
3000257 THC-COOH, Cord, Qual 61063-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Marijuana Metabolite, Umbilical Cord Tissue, Qualitative